Results 71 to 80 of about 765,112 (149)

Abnormalities affecting tyrosine kinase signalling in atypical myeloproliferative disorders [PDF]

open access: yes, 2009
The myeloproliferative disorders (MPDs) are a group of haematopoietic stem cell diseases, characterised by proliferation of one or more cells of the myeloid lineage.
Hidalgo-Curtis, Claire
core   +1 more source

Management of chronic urticaria: Current status and future prospect

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Chronic urticaria is driven by mast cell activation through autoimmune, inflammatory, and neuroimmune pathways. A structured approach combining diagnosis, patient‐reported outcomes, stepwise therapy, treatment optimization, monitoring and emerging targeted agents may improve disease control and enable more personalized management.
Andaç Salman   +15 more
wiley   +1 more source

Characterization of All Possible Single-Nucleotide Change Caused Amino Acid Substitutions in the Kinase Domain of Bruton Tyrosine Kinase

open access: yes, 2015
Knowledge about features distinguishing deleterious and neutral variations is crucial for interpretation of novel variants. Bruton tyrosine kinase (BTK) contains the highest number of unique disease-causing variations among the human protein kinases ...
Faisal, Imrul   +11 more
core   +1 more source

Targeted therapies in pemphigus vulgaris: Emerging horizons beyond rituximab

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Rituximab‐refractory pemphigus vulgaris is driven by B‐cell repopulation, plasma‐cell persistence, IgG4 autoantibodies and anti‐drug antibodies. This review evaluates five emerging targeted classes acting at successive steps of disease: next‐generation anti‐CD20 antibodies, DSG3‐CAAR T cells, BTK inhibitors, BAFF/APRIL inhibitors and FcRn antagonists ...
Rhea Ahuja, Dedee Murrell
wiley   +1 more source

Reactogenicity and Immunogenicity of RSV Vaccines in Immunocompromised Individuals With Hematological Malignancies

open access: yesTransplant Infectious Disease, EarlyView.
In adults with hematologic malignancies, RSV vaccination was safe and induced antibody and T‐cell responses. However, antibody levels were lower and declined more rapidly than in healthy controls. While early immune responses were evident, reduced magnitude and durability of protection suggest the need for optimized vaccination strategies in this high ...
Alisse Hannaford   +32 more
wiley   +1 more source

Real‐World Treatment Patterns, Tolerability, and Outcomes Among Patients With CLL/SLL Treated With First‐Line Ibrutinib, Acalabrutinib, or Zanubrutinib in the US Community Oncology Setting: A Retrospective Cohort Study

open access: yeseJHaem, Volume 7, Issue 6, December 2026.
ABSTRACT Background Covalent Bruton tyrosine kinase inhibitors (cBTKis) are standard first‐line (1L) therapies for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). In clinical trials, second‐generation (2G) cBTKis demonstrated better tolerability than ibrutinib, particularly regarding cardiotoxicity; however, real‐world evidence on ...
John M. Burke   +10 more
wiley   +1 more source

Protein recruitment to receptor tyrosine kinase-mediated early signalling complexes. [PDF]

open access: yes, 2007
Receptor tyrosine kinase (RTK) signalling regulates the activation of numerous cellular processes in response to various external stimuli. Spatio-temporal regulation of protein recruitment to activated tyrosine kinase receptors is important for the ...
Schller, A.C.
core  

Phosphatidylinositol 3-kinase-dependent translocation of phospholipase Cgamma2 in mouse megakaryocytes is independent of Bruton tyrosine kinase translocation

open access: yes, 2001
Activation of the collagen receptor glycoprotein VI (GPVI) by a collagen-related peptide (CRP) induces stimulation of platelets and megakaryocytes through the phosphatidylinositol (PI) 3-kinase–dependent pathway leading to activation of Bruton tyrosine ...
Jonathan I. Wilde   +14 more
core   +1 more source

Atrial Fibrillation During Zanubrutinib Treatment in Chronic Lymphocytic Leukemia With a Historical Ibrutinib Control

open access: yeseJHaem, Volume 7, Issue 6, December 2026.
ABSTRACT Introduction Atrial fibrillation (AF) complicates Bruton tyrosine kinase inhibitor therapy in chronic lymphocytic leukemia. Methods We retrospectively evaluated 679 zanubrutinib‐treated patients across 52 Italian centers, with 354 historical ibrutinib‐treated controls. Shanafelt AF scores were assessed.
Andrea Visentin   +92 more
wiley   +1 more source

Vaccine responses in patients with chronic lymphocytic leukemia on treatment with Bruton Tyrosine Kinase Inhibitors: a focused review

open access: yesHematology, Transfusion and Cell Therapy, 2022
Mohammad Ammad Ud Din   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy